---
layout: archive
title: "Projects"
permalink: /projects/
author_profile: true
redirect_from:
  - /projects
---

<h4>An overview of our (international) projects and collaborations</h4>

<h2>SPIDERR-Horizon EU</h2>
<div style="height: 200px;">
<a href="https://knevel-lab.github.io">
<img src="/images/SPIDeRR_logo_crop.png" alt="EU Horizon project SPIDeRR" class="applink">
</a>
<p><b>Lead: </b>Rachel Knevel, Dept of Rheumatology LUMC, the Netherlands</p>
<p><b>Our role: </b>Project lead</p>
<p><b>Aim: </b>Aim: SPIDeRR aims to disentangle the real-life complexity of early diagnosis of rheumatic diseases by considering the complete web of factors influencing patientsâ€™ symptoms. It will deliver:
-a symptom checker for patients,
-a decision support tool for (primary) care providers providing guiding additional examination and referral decisions -a patient-patient similarity network to optimise diagnostic groups in rheumatology and support treatment decision
</p>
</div>
<hr>

<h2>Digiprevent - EITHealth</h2>
<div style="height: 200px;">
<a href="https://eithealth.eu/product-service/digiprevent/">
<img src="/images/EITHealth.jpg" alt="Rachel Knevel" class="applink">
</a>
<p><b>Lead: </b>Lars Klareskog, Dept of Rheumatology Karolinska Institute Zweden</p>
<p><b>Our role: </b>Implementation</p>
<p><b>Aim: </b>DigiPrevent enables personalised prevention in RA, combined with much earlier treatment if arthritis ensues, through a new digital screening procedure, Rheumatic and a blood based diagnostic tool, Rheuma-multiplex.</p>
</div>
<hr>

<h2>SQUEEZE - Horizon EU</h2>
<div style="height: 200px;">
<!-- <a href="https://cordis.europa.eu/project/id/101095052"> OLD LINK -->
<a href="https://squeeze-project.eu/">
<img src="/images/SQUEEZE_logo.jpg" alt="EU Horizon project SQUEEZE" class="applink">
</a>
<p><b>Lead: </b>Daniel Aletaha, Dept of Rheumatology, Vienna</p>
<p><b>Our role: </b>Analytic lead</p>
<p><b>Aim: </b>SQUEEZE integrates to validate clinical, laboratory, molecular, digital and behavioural biomarkers to enable the recognition of patients with high likelihood of response to treatment and the selection of the drug with highest chance of benefit for an individual patient; and as such improve efficacy and safety of existing therapies (by squeezing the most out of existing drugs) in synergy with other EU-wide activities</p>
</div>
<hr>

<h2>RTCure - IMI</h2>
<div style="height: 200px;">
<a href="https://www.rtcure.com/">
<img src="/images/RTCure.jpg" alt="Rachel Knevel" class="applink">
</a>
<p><b>Lead: </b>Lars Klareskog, Dept of Rheumatology Karolinska Institute Zweden</p>
<p><b>Our role: </b>Bioinformatic lead</p>
<p><b>Aim: </b>Prevent RA or its progression by inhibiting the expansion of pathogenic autoimmune responses through immune tolerising treatments.</p>
</div>
<hr>
